ArticleJournal of veterinary internal medicine2026
Combination of azathioprine and prednisolone as a treatment for meningoencephalomyelitis of unknown origin in dogs: 54 cases.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInformation regarding efficacy of combination of azathioprine and prednisolone in treating meningoencephalomyelitis of unknown origin (MUO) in dogs is limited. HYPOTHESIS/
objectivesTo report median survival time in dogs with MUO treated with a combination of azathioprine and prednisolone and assess its tolerability. ANIMALS: Ninety-two dogs diagnosed with MUO between January 2011 and December 2022 that received azathioprine and prednisolone.
methodsA retrospective medical record review was conducted. Diagnosis of MUO was based on clinical signs, magnetic resonance imaging features, and cerebrospinal fluid analysis.
resultsMedian survival time was 1289 days (range: 30-3356). Median survival time did not differ significantly between dogs that presented with seizures (n = 12; 308 days) and those without seizures (1289 days; P = .74), nor between dogs that experienced relapses (n = 20; 1153 days) and those that did not (1697 days; P = .58). Myelosuppression occurred in 10 dogs and hepatotoxicity in 1 dog. In 9 dogs, adverse effects resolved with drug discontinuation or dose reduction. One dog died from hepatic necrosis and 1 from myelosuppression. CONCLUSIONS AND CLINICAL IMPORTANCE: Combination of azathioprine and prednisolone is associated with long median survival times for dogs with MUO in this study. Adverse drug reactions were reversible in most cases but can be fatal in some. Therefore, hematological values and hepatic variables should be monitored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.